Pharma Acquisition: Mankind Pharma Expands with Bharat Serums and Vaccines Deal
Pharma Acquisition: Mankind's Strategic Growth
Mankind Pharma on Wednesday announced the completion of its acquisition of Bharat Serums and Vaccines Ltd (BSV) for Rs 13,768 crore. This significant move positions Mankind as a market leader in the women's health and fertility drug sectors, while also providing access to high-entry-barrier products in the critical care segment, backed by established complex R&D technology platforms.
Significance of the Acquisition
- BSV has developed recombinant and niche biologic products, showcasing strong R&D capabilities.
- The collaboration enhances access to specialized and indigenously developed complex treatments for patients in India and globally.
- Mankind Pharma welcomes over 2,500 BSV employees, integrating them into its operations.
Rajeev Juneja, Vice-chairman and Managing Director of Mankind Pharma, stated that this acquisition represents a new chapter for the company, enabling growth and maximizing potential in the healthcare sector. Sanjiv Navangul, MD & CEO of BSV, echoed this sentiment, highlighting the strength of the merged entities in improving patient access.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.